Form 4: Akari Therapeutics Director Acquires Significant Stake in Private Placement
SEC Form 4 Filing
Samir Rashmikant Patel, a director of Akari Therapeutics Plc, acquired 1,326,258,000 ordinary shares and warrants in a private placement on May 31, 2024.
Summary
- On May 31, 2024, Samir Rashmikant Patel, a director of Akari Therapeutics Plc, acquired 1,326,258,000 ordinary shares and warrants to purchase an additional 1,326,258,000 ordinary shares.
- The acquisition was part of a private placement by Akari Therapeutics.
- The purchase price was $0.0009425 per ordinary share and accompanying warrant.
- The warrants have an exercise price of $0.000895 per ordinary share and expire on May 31, 2027.
- Patel also indirectly owns 3,411,495,500 ordinary shares through PranaBio Investments LLC.
Sentiment
Score: 5
Explanation: Neutral sentiment as the document simply reports a transaction. The director's purchase could be seen as a positive signal, but more context is needed.
Positives
- A director's increased investment could signal confidence in the company's future prospects.
Risks
- The document does not provide enough information to assess the overall financial health or future prospects of Akari Therapeutics.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders.
Stakeholder Impact
- The transaction could potentially impact shareholders' perception of the company.
Key Dates
| Date | Description |
|---|---|
| December 13, 2023 | Date of Power of Attorney execution. |
| May 29, 2024 | Date of Securities Purchase Agreement. |
| May 31, 2024 | Date of the transaction (acquisition of shares and warrants). |
| May 31, 2027 | Expiration date of the warrants. |
| June 04, 2024 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.